10.02 Combined anti-angiogenic treatment to increase intratumoral persistence of CAR T-cells in lung cancer brain metastases

• M Subklewe,
• T Xu,
• N Thon,
• S Langer,
• L von Baumgarten,
• C Eberle,
• VR Buchholz,
• J Blobner,
• L Dengler,
• JJ Herold,
• A Mühlbauer,
• KJ Müller,
• N Teske,
• P Karschnia,
• H Ishikawa-Ankerhold,
• J Tonn

Affiliations

M Subklewe

3Department of Medicine III, Klinikum der Universität München, Munich, Germany

T Xu

Department of Orthopaedics, Chang-Zheng Hospital, The Second Military Medical University, Shanghai, China, 200003

N Thon

3University Hospital of Munich, Neurosurgery, Munich, Germany

S Langer

Institute of Human Genetics, Technical University München and GSF, Neuherberg, Germany

L von Baumgarten

3Department of Neurology, University Hospital, LMU Munich, Munich, Germany

C Eberle

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

VR Buchholz

6Institute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany

J Blobner

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

L Dengler

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

JJ Herold

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

A Mühlbauer

2Technical University of Munich (TUM), Munich, Germany

KJ Müller

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

N Teske

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

P Karschnia

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

H Ishikawa-Ankerhold

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany

J Tonn

1University Hospital of the Ludwig-Maximilians University Munich (LMU), Munich, Germany